Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...

In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug ...

Team of Chinese medical experts says they can produce anticancer cells directly inside the human body using gene therapy ...

Sarepta Therapeutics refuses the FDA request to halt its gene therapy shipments following a third patient death, challenging ...

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Genascence’s GNSC-001 for knee osteoarthritis receives US FDA regenerative medicine advanced therapy designation: Palo Alto, California Saturday, July 19, 2025, 16:30 Hrs [IST] ...

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...

Rocket Pharma receives US FDA regenerative medicine advanced therapy designation for RP-A601 gene therapy: Cranbury, New Jersey Saturday, July 19, 2025, 15:00 Hrs [IST] Rocket Pha ...

The FDA asked Sarepta Therapeutics to halt shipments of its Elevidys gene therapy after a patient's death linked to a similar treatment. Sarepta will continue shipments for ambulatory patients but ...

(NASDAQ: OCGN) has announced that the first patient has been dosed in its Phase 2/3 GARDian3 clinical trial evaluating ...